zemirciclib   Click here for help

GtoPdb Ligand ID: 11782

Synonyms: AZD-4573 | AZD4573 | compound 24 [PMID: 33306391]
PDB Ligand
Compound class: Synthetic organic
Comment: AZD4573 is a potent inhibitor of cyclin dependent kinase 9 (CDK9), that was designed for potential to treat haematological malignancies [1-3]. Inhibition of CDK9 disrupts the expression of cancer-promoting genes such as MCL-1, and induces apoptosis. The chemical structure of AZD4573 matches that of the INN zemirciclib (proposed INN list 130, Feb. 2024).
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 2
Rotatable bonds 6
Topological polar surface area 88.91
Molecular weight 429.19
XLogP 3.17
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CC(=O)N[C@@H]1CCC[C@@H](C1)C(=O)Nc1ncc(c(c1)c1cnn2c1CC(C2)(C)C)Cl
Isomeric SMILES CC(=O)N[C@@H]1CCC[C@@H](C1)C(=O)Nc1ncc(c(c1)c1c2CC(Cn2nc1)(C)C)Cl
InChI InChI=1S/C22H28ClN5O2/c1-13(29)26-15-6-4-5-14(7-15)21(30)27-20-8-16(18(23)11-24-20)17-10-25-28-12-22(2,3)9-19(17)28/h8,10-11,14-15H,4-7,9,12H2,1-3H3,(H,26,29)(H,24,27,30)/t14-,15+/m0/s1
InChI Key AVIWDYSJSPOOAR-LSDHHAIUSA-N
References
1. Alcon C, Manzano-Muñoz A, Montero J. (2020)
A New CDK9 Inhibitor on the Block to Treat Hematologic Malignancies.
Clin Cancer Res, 26 (4): 761-763. [PMID:31843752]
2. Barlaam B, Casella R, Cidado J, Cook C, De Savi C, Dishington A, Donald CS, Drew L, Ferguson AD, Ferguson D et al.. (2020)
Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological Malignancies.
J Med Chem, 63 (24): 15564-15590. [PMID:33306391]
3. Cidado J, Boiko S, Proia T, Ferguson D, Criscione SW, San Martin M, Pop-Damkov P, Su N, Roamio Franklin VN, Sekhar Reddy Chilamakuri C et al.. (2020)
AZD4573 Is a Highly Selective CDK9 Inhibitor That Suppresses MCL-1 and Induces Apoptosis in Hematologic Cancer Cells.
Clin Cancer Res, 26 (4): 922-934. [PMID:31699827]